Arvinas: Wall Street Bracing for a Miss That May Not Matter

Arvinas Inc (ARVN) is scheduled to report Q1 2026 earnings on May 7, 2026, before market open, with analysts expecting a loss of $0.95 per share. The biotech's upcoming report arrives at a critical juncture as investors weigh the company's strategic refocus on four core clinical programs against a deteriorating analyst sentiment backdrop and mounting losses. With the FDA's PDUFA decision on vepdegestrant just weeks away and multiple pipeline readouts expected throughout 2026, this earnings call will test whether management can restore confidence after last quarter's significant miss.

Part 1: Earnings Preview

Arvinas Inc is a clinical-stage biopharmaceutical company pioneering protein degradation therapies using its proprietary PROTAC® technology platform, with a pipeline spanning oncology and neuroscience indications. The company's lead asset, vepdegestrant, is under FDA review for ESR1-mutated breast cancer, while earlier-stage programs target neurological disorders including Parkinson's disease.

For Q1 2026, analysts expect Arvinas to report a loss of $0.95 per share when results are released before market open on May 7, 2026. This compares to the most recently reported quarter (Q4 2025), where the company posted an actual loss of $1.10 per share—missing estimates by 100% and marking a sharp reversal from the prior quarter's performance. Year-over-year, the expected Q1 2026 loss of $0.95 represents a dramatic deterioration from the $1.14 profit reported in Q1 2025, translating to a -183.33% growth rate.

Three key themes define this earnings story:

Vepdegestrant FDA Decision and Commercialization Strategy: With the PDUFA date set for June 5, 2026, investors are focused on any updates regarding the NDA review process and the company's plans following its September 2025 decision to seek a third-party commercialization partner. Recent analyst downgrades reflect heightened uncertainty around the asset's commercial prospects amid intensifying competitive pressure in the ER+/HER2- breast cancer space. HC Wainwright's recent estimate cuts underscore concerns about the timeline and economics of any potential partnership.

Pipeline Execution and 2026 Data Catalysts: Management's strategic refocus on four core Phase 1 programs—ARV-102 (LRRK2 degrader for Parkinson's and PSP), ARV-806 (KRAS degrader), ARV-393 (BCL6 degrader), and ARV-027—positions 2026 as a data-rich year. The planned initiation of a Phase 1B trial in progressive supranuclear palsy (PSP) for ARV-102 in H1 2026, with potential for a registrational trial by year-end, represents a critical inflection point. Analysts are watching for clarity on regulatory feedback and trial design that could accelerate the neuroscience portfolio.

Cash Runway and Operational Discipline: Following a 15% workforce reduction in September 2025 and $91.9 million in share repurchases, the company ended Q4 2025 with $685.4 million in cash—down from $1.04 billion at year-end 2024. Management's guidance for a cash runway extending into the second half of 2028 will be scrutinized, particularly given the $261 million operational cash burn in 2025. Investors want confirmation that the company can reach key value-driving milestones without additional dilutive financing.

Analysts remain divided heading into the print. While 10 firms maintain Strong Buy ratings, the consensus has deteriorated over the past month, with one analyst downgrading to Strong Sell. The average price target of $15.06 implies 47% upside, but the wide range ($6.00 to $24.00) reflects deep uncertainty about execution risk and the ultimate value of the vepdegestrant asset.

Part 2: Historical Earnings Performance

Arvinas has delivered a volatile earnings track record over the past eight quarters, with results swinging dramatically between beats and misses. The most recent quarter (Q4 2025) saw the company report a loss of $1.10 per share against estimates of $0.55, representing a -100% miss—the worst performance in the dataset. This marked a sharp reversal from the prior three quarters, which had all exceeded expectations.

Looking back further, Q3 2025 delivered a modest +36.00% beat with a loss of $0.48 versus the $0.75 estimate, while Q2 2025 came in nearly in line with a +3.45% beat (loss of $0.84 versus $0.87 estimate). The standout performance came in Q1 2025, when Arvinas reported a profit of $1.14 per share against an expected loss of $0.86—a massive +232.56% beat driven by collaboration revenue recognition.

The pattern reveals no consistent trend: the company has alternated between significant beats and misses, with four of the past eight quarters exceeding estimates and four falling short. The magnitude of surprises has been substantial in both directions, ranging from the Q1 2025 upside surprise of over 200% to the most recent quarter's 100% miss. This volatility reflects the lumpy nature of collaboration revenue and the unpredictability of milestone payments, making quarter-to-quarter results difficult to forecast. Investors should expect continued earnings volatility as the company transitions from a research-stage operation dependent on partnership income to a potential commercial entity.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Arvinas typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Arvinas earnings reveals significant volatility, with an average absolute Day 0 move of 7.19% and Day +1 move of 4.37%. The most dramatic reactions occurred in May 2025, when the stock plunged 24.84% on Day 0 following results, then partially recovered with a 6.78% gain on Day +1. Conversely, the most recent report in February 2026 saw a muted 0.57% Day 0 move despite the significant earnings miss, followed by a 7.48% Day +1 rally—suggesting investors looked past the quarterly results to focus on pipeline developments.

The data shows Day 0 moves have ranged from a 24.84% decline to a 6.42% gain, with an average intraday range of 10.19%. Day +1 follow-through has been somewhat less volatile, averaging 7.99% in range. Notably, the direction of Day 0 and Day +1 moves has frequently diverged, as seen in the May 2025, February 2025, and May 2024 reports, indicating that initial reactions are often reassessed as investors digest the full implications of results and guidance. Given this pattern, investors should anticipate substantial price swings in both directions around the upcoming release, with the potential for meaningful reversals between the first and second trading sessions.

Part 2.2: Options Market Expected Move

The options market is pricing in a 9.86% expected move for the May 15, 2026 expiration (9 days out), which sits above the 7.19% average Day 0 move but below the 10.19% average Day 0 range observed historically. This suggests options traders are anticipating above-average volatility for this particular release, though not at the extreme levels seen in some prior quarters like May 2025's 24.84% Day 0 decline.

Part 3: What Analysts Are Saying

Analyst sentiment on Arvinas has deteriorated heading into the Q1 2026 earnings release, with the consensus average recommendation standing at 3.80 (between Hold and Buy) across 20 analysts. The current breakdown shows 10 Strong Buy ratings, 8 Hold ratings, and 2 Strong Sell ratings, with no Moderate Buy or Moderate Sell positions. The average price target of $15.06 implies approximately 47% upside from the current price of $10.26, though the wide range of targets—from a low of $6.00 to a high of $24.00—reflects deep disagreement about the company's prospects.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.90 to 3.80 as one analyst downgraded from Hold to Strong Sell. This marks a continuation of the negative trend that began following the company's September 2025 decision to seek a third-party partner for vepdegestrant commercialization. Recent research from HC Wainwright exemplifies the cautious stance, with the firm reducing Q1 2026 EPS estimates from a loss of $0.89 to $0.96 and cutting full-year 2026 estimates from $3.21 to $3.93 per share.

The deterioration in sentiment appears driven by three factors: heightened competitive concerns around vepdegestrant's commercial potential in a crowded breast cancer market, uncertainty around partnership economics and timing, and questions about whether the company's cash runway will support advancement to key pipeline milestones without additional dilution. While the 10 Strong Buy ratings indicate some analysts remain believers in the PROTAC platform's long-term potential—particularly for the neuroscience programs—the growing number of Hold and Sell ratings suggests the Street is adopting a wait-and-see posture until execution risk diminishes.

Part 4: Technical Picture

Arvinas enters its Q1 2026 earnings report in a deteriorating technical position, with the Barchart Technical Opinion showing a 56% Sell signal—a significant weakening from the 16% Buy signal just one month ago and the 40% Sell reading last week. This rapid deterioration reflects mounting downside momentum as the stock has failed to hold key support levels.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative heading into the earnings release
• Medium-term (50% Sell): Matching sell signal suggests the intermediate-term trend has also weakened, with no signs of stabilization
• Long-term (50% Sell): Consistent sell reading across all timeframes points to broad-based technical deterioration

Trend Characteristics: The Soft Strongest trend designation indicates a weak but accelerating downtrend, suggesting the stock is vulnerable to further downside if earnings disappoint or guidance fails to inspire confidence.

At $10.26, ARVN is trading below all major moving averages: the 5-day ($10.41), 10-day ($10.32), 20-day ($10.59), 50-day ($11.43), 100-day ($11.92), and 200-day ($10.49). The stock's position beneath even its short-term moving averages signals persistent selling pressure, while the distance from the 50-day and 100-day averages (down 10.2% and 13.9% respectively) indicates a meaningful technical breakdown.

The 200-day moving average at $10.49 represents immediate overhead resistance just 2.2% above current levels, while the 20-day at $10.59 marks a secondary barrier. On the downside, the recent low near $10.00 represents psychological support. The overall technical setup is cautionary heading into earnings, with the stock showing no signs of stabilization and all momentum indicators pointing lower. Unless results and guidance significantly exceed expectations, the path of least resistance appears to be further downside, particularly given the options market's expectation of a nearly 10% move and the stock's history of volatile post-earnings reactions.